[RFA-NS-26-001] Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Description

Titolo: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) Numero dell'opportunità: RFA-NS-26-001 Stato: aperto (posted) Tipo di opportunità: Discretionary Ente: National Institutes of Health — Department of Health and Human Services Tipo di finanziamento: Cooperative Agreement Categoria: Health Programma (ALN): 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders Pubblicato il: 2026-05-04 Scadenza per le domande: 2026-11-10 Finanziamento totale stimato: 40,000,000 USD Numero di finanziamenti attesi: 4 Cofinanziamento richiesto: no Chi può fare domanda: Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; City or township governments; Public housing authorities/Indian housing authorities; County governments; Special district governments; Native American tribal governments (Federally recognized); Independent school districts; Small businesses; Native American tribal organizations (other than Federally recognized tribal governments); Others (see text field entitled "Additional Information on Eligibility" for clarification); State governments; For profit organizations other than small businesses Altre condizioni di eleggibilità: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Descrizione: The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS. Contatto: [email protected]

Sectors

Source

Source: grants.gov